ALT flares were linked to HBsAg reduction, seroclearance and seroconversion: interim results from a phase IIb study in chronic hepatitis B patients with 24-week treatment of subcutaneous PD-L1 Ab ASC22 (Envafolimab) plus nucleos (t)ide analogs

ALT) levels throughout the study; 2 participants in each regimen had grade 1 ALT elevations.No treatment-related serious AEs were reported. Conclusion:These preliminary data support that a longer duration of treatment with VIR-2218 results in deeper and more sustained reductions in HBsAg.In both regimens of VIR-2218, no differences in safety or tolerability were observed.